Key statistics
As of last trade Ocugen Inc (2H51:MUN) traded at 1.19, -28.28% below its 52-week high of 1.66, set on Jan 15, 2026.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
| Open | 1.19 |
|---|---|
| High | 1.19 |
| Low | 1.19 |
| Bid | 1.19 |
| Offer | 1.22 |
| Previous close | 1.18 |
| Average volume | 67.54k |
|---|---|
| Shares outstanding | 327.89m |
| Free float | 319.89m |
| P/E (TTM) | -- |
| Market cap | 452.49m USD |
| EPS (TTM) | -0.2167 USD |
Data delayed at least 15 minutes, as of Feb 11 2026 07:00 GMT.
More ▼
Announcements
- Ocugen Appoints Rita Johnson-Greene to Chief Financial Officer
- Ocugen, Inc. Announces Closing of $22.5 Million Underwritten Registered Direct Offering of Common Stock
- Ocugen, Inc. Announces Pricing of $22.5 Million Offering of Common Stock
- Ocugen Announces Positive Preliminary Phase 2 Data from OCU410 Modifier Gene Therapy for Geographic Atrophy Secondary to Dry Age-Related Macular Degeneration
- Ocugen to Host Webcast on Thursday, January 15 at 8:30 a.m. ET to Discuss OCU410 Phase 2 Clinical Trial Data
- Ocugen Announces Publication of Phase 1 GARDian1 Trial Results for OCU410ST Modifier Gene Therapy
- Ocugen CEO to Present at J.P. Morgan 2026 Healthcare Conference
- Ocugen CEO to Present at Oppenheimer Movers in Rare Disease Summit
- Ocugen CEO to Present at NobleCon21—Noble Capital Markets’ Twenty-First Annual Emerging Growth Equity Conference
- Ocugen Provides Business Update with Third Quarter 2025 Financial Results
More ▼
